Other research analysts have also recently issued reports about the company. Oppenheimer lowered their price objective on 2U from $83.00 to $67.00 and set an “outperform” rating for the company in a research report on Wednesday, May 8th. Evercore ISI began coverage on Homology Medicines in a research report on Thursday, April 11th. They set an “outperform” rating and a $29.00 price objective for the company. Chardan Capital set a $55.00 price objective on Editas Medicine and gave the stock a “buy” rating in a research report on Sunday, June 16th. Finally, Zacks Investment Research raised Garrett Motion from a “sell” rating to a “hold” rating in a research report on Friday, May 10th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Editas Medicine currently has an average rating of “Buy” and a consensus target price of $37.80.
NASDAQ:EDIT opened at $24.85 on Friday. The business’s 50-day simple moving average is $22.62. The firm has a market cap of $1.22 billion, a PE ratio of -10.67 and a beta of 2.53. Editas Medicine has a 1 year low of $17.80 and a 1 year high of $38.30. The company has a current ratio of 8.46, a quick ratio of 8.46 and a debt-to-equity ratio of 0.07.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Winslow Evans & Crocker Inc. boosted its position in shares of Editas Medicine by 398.7% in the 1st quarter. Winslow Evans & Crocker Inc. now owns 1,576 shares of the company’s stock valued at $40,000 after purchasing an additional 1,260 shares during the period. Joseph P. Lucia & Associates LLC acquired a new stake in shares of Editas Medicine in the 1st quarter valued at about $65,000. Bronfman E.L. Rothschild L.P. boosted its position in shares of Editas Medicine by 48.7% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 3,055 shares of the company’s stock valued at $70,000 after purchasing an additional 1,000 shares during the period. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Editas Medicine in the 4th quarter valued at about $109,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of Editas Medicine by 10.4% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,697 shares of the company’s stock valued at $139,000 after purchasing an additional 537 shares during the period. 75.43% of the stock is owned by hedge funds and other institutional investors.
About Editas Medicine
Editas Medicine, Inc operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas.
Further Reading: Cash Asset Ratio
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.